Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

314
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
314
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

452
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
452
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

138
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
138
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

156
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
156

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same author

Blood Never Lies: The PopPK-Based Lie Detector.

Clinical pharmacokinetics·2026
Same author

External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Population pharmacokinetic modelling of amoxicillin in human breast milk-A contribution from the ConcePTION project.

British journal of clinical pharmacology·2026
Same author

Correction: Advanced strategies for detecting acid sphingomyelinase deficiency type B with attenuated phenotypes.

Orphanet journal of rare diseases·2025
Same author

Allograft nephrectomy: Indications and surgical techniques. Association Française d'Urologie and Société Francophone de Transplantation guidelines.

The French journal of urology·2025

Related Experiment Video

Updated: Jan 10, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

391

Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD.

Sahira Chaiben1, Peggy Gandia1,2, Thibaut Jamme3

  • 1INTHERES, University of Toulouse, INRAE, ENVT, Toulouse, France.

CPT: Pharmacometrics & Systems Pharmacology
|November 21, 2025
PubMed
Summary

Personalizing infliximab (a monoclonal antibody) dosing is crucial due to high variability. This study identified patient-specific pharmacokinetic models to optimize infliximab dosage, balancing safety, efficacy, and cost.

Keywords:
AI‐guided dosingCrohn's diseaseimmunopathologyinfliximabpharmacokinetics

More Related Videos

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
11:09

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry

Published on: April 17, 2018

10.6K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

17.4K

Related Experiment Videos

Last Updated: Jan 10, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

391
An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
11:09

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry

Published on: April 17, 2018

10.6K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

17.4K

Area of Science:

  • Pharmacology
  • Immunology
  • Biotechnology

Background:

  • Infliximab, a monoclonal antibody for immune-mediated diseases, exhibits significant interpatient pharmacokinetic variability.
  • This variability necessitates personalized dosing to optimize safety, efficacy, and cost-effectiveness by avoiding prolonged exposure and adverse effects.

Purpose of the Study:

  • To identify patient-specific pharmacokinetic models for infliximab.
  • To assess the impact of selecting different models on individualized infliximab dosing strategies.

Main Methods:

  • Retrospective analysis of adult Crohn's disease patients on infliximab.
  • Screening of published pharmacokinetic models and evaluation of model-patient compatibility using Multivariate Exact Discrepancy and Monte Carlo simulations.
  • Calculation of median and 90% confidence intervals for doses required to achieve a target infliximab exposure.

Main Results:

  • No single pharmacokinetic model was compatible with all patients.
  • Dosing recommendations varied significantly across compatible models, highlighting inter-model differences.
  • Patient variability contributed to dosing imprecision, with calculated median doses averaging 9.25 mg/kg.

Conclusions:

  • A concentration-based method using pharmacokinetic profiling enables personalized infliximab dosing.
  • Patients can be categorized based on model compatibility, guiding whether to use manufacturer recommendations or intensified therapeutic drug monitoring.